ClinicalTrials.gg
RecruitingNCT07219771MOTION-PUpdated Oct 16, 2026

A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P)

A Phase 3 interventional study of PTP-01 and Placebo control / saline vehicle in Knee Osteoarthritis, sponsored by Doron Therapeutics Inc.. Recruiting at 18 sites in 2 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Doron Therapeutics Inc. · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 16, 2026Site recruiting status changedPrimary completion moved+6 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 796 studies in Osteoarthritis, Knee with a site in United States — 109 open to participants now, 152 under way, 15 of them phase 3. Osteoarthritis, Knee · United States.

Planned enrollment
111th of 691
300 · median 72
Started
2025
with 36 others
Phase 3
76 of 796
6 open now
Primary completion
2027-06
later than 74 of 151 live
Registered
767th of 796
by date

Among the 796 studies in Osteoarthritis, Knee with a site in United States, this one is the 111th largest by planned enrollment of the 691 interventional ones that give a count, is one of 37 that started in 2025, is one of 76 in phase 3, reaches primary completion later than 74 of the 151 other live ones, and was the 767th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

109 of the 796 studies in Osteoarthritis, Knee with a site in United States are open now. Recruiting first, the newest first:

104 more — sign in →

All 109 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 796 studies in Osteoarthritis, Knee with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, prospective, randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of intra-articular administration of PTP-001 (MOTYS) for the treatment of knee osteoarthritis.

The purpose of the trial is to evaluate the efficacy, safety, and tolerability of a single intra-articular injection of PTP-001 compared to placebo over a 52-week period in participants with radiographic and symptomatic knee OA.

Read the detailed description

The participants will be randomized in a 1:1 ratio to receive one of either PTP-001 or placebo injection. Each participant will be administered a single dose of investigational product (IP) (active or placebo) on Day 1.

The trial will consist of a Screening period (up to 28 days prior to treatment), a treatment phase (1 day) and a follow-up phase (12 months following treatment). A total of at least 260 participants are planned to be randomized (130 participants/group).

03

Conditions studied

  • Knee Osteoarthritis

Keywords

  • Osteoarthritis
  • Knee Osteoarthritis
04

Who can participate

The criteria were revised on the registry on Oct 16, 2026. See what changed

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and females aged 40 to 80 years.
  2. Presenting with symptomatic knee OA with Kellgren-Lawrence (KL) radiographic classification of 2 or 3 (mild or moderate), as assessed by the central reading facility.
  3. Primary source of pain throughout the body is due to OA in the target knee.
  4. Target knee pain ≥ 20 and ≤ 40 out of 50 on the WOMAC® numerical rating scale (NRS) 3.1 pain questionnaire (sum of 5 questions) at Screening and Baseline.
  5. Onset of symptomatic OA of the target knee was at least 6 months prior to Screening.
  6. Insufficient, failed response, or intolerance to analgesics and / or non-steroidal anti-inflammatory drugs (NSAIDs), as reported by the participant.
  7. If female, must meet all of the following:

    1. Not breast feeding,
    2. Not planning to become pregnant during the study,
    3. Must abstain from ova / egg donation during the study,
    4. If of , must have a negative pregnancy test result within 72 hours prior to receiving the intra-articular injection, and must commit to the use of a highly effective form of for at least 90 days after the injection.
  8. Willing to use acetaminophen as the only oral rescue (as needed) analgesic medication for target knee pain during the study.
  9. Willing to abstain from taking any illicit or unauthorized medications for treatment of OA or any other concurrent condition during the study.
  10. Willing to comply with study visit schedule and post-injection restrictions.
  11. Written is obtained from the participant.

Exclusion criteria

Exclusion Criteria:

  1. Participant is non-ambulatory (unable to walk > 50 feet / 15 meters without assistance).
  2. Clinically severe obesity as defined by the National Institutes of Health ( ≥ 40 kg/m2) at Screening and / or Baseline.
  3. Contralateral (non-target) knee pain is >10 out of 50 on the WOMAC® NRS 3.1 pain questionnaire (sum of 5 questions) at Screening or at Baseline.
  4. At Baseline, difference between the first Baseline and second Baseline WOMAC pain scores is > 3 for the target knee.
  5. Contralateral (non-target) knee pain is experienced for ≥ 14 days in the month.
  6. Use of any analgesia during the (5 half-lives) at Screening or Baseline.
  7. Participation in any study within 30 days (or 5 half-lives, whichever is longer) prior to Screening or planning to participate in any other investigational drug or device clinical trials within 30 days of study completion.
  8. Currently requires use of a lower extremity prosthesis and / or a structural knee brace (ie, a knee brace that contains hardware).
  9. effusion of the target knee at either the Screening or Baseline visits as determined by physical examination (eg, ballotable patella or positive bulge sign).

    Note: Participants presenting with effusion may be enrolled in the study after undergoing knee aspiration to remove excess fluid in the target joint.

  10. Clinical and/or radiographic evidence (other than that performed for Kellgren-Lawrence eligibility assessment) of severe (excessive) malalignment of the tibial-femoral axis, as assessed by the Investigator.
  11. Presence of active infection in the target knee or systemic infection requiring treatment within the 3 months prior to Screening.
  12. Clinical diagnosis of inflammatory arthritis (eg, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus, etc.) established by clinical history, examination, or serology.
  13. Participant is receiving, has received, or plans to receive any of the following therapies:

    1. Prior administration of hyaluronic acid, extended-release (eg, Zilretta®), -rich plasma (PRP), or stem cell therapies by intra-articular injection(s) of the target knee within 6 months prior to Screening.
    2. Prior administration of corticosteroid by intra-articular injection of the target knee within 3 months prior to Screening or into any other joint within 30 days prior to Screening.
    3. Current chronic systemic use of corticosteroids in doses exceeding the equivalent of 10 mg prednisolone daily.
    4. Treatment with any investigational therapy (drug, device, or biologic) within 3 months prior to Screening or is planned for the duration of the study.
    5. Treatment with medication (not including mild transient immunosuppressants such as corticosteroids) or chemotherapy within the past 5 years.
  14. Chronic use of narcotics or alcohol abuse within the past 6 months prior to Screening.
  15. Surgery to either knee (including arthroscopy) within 6 months prior to receiving the intra-articular injection or planned surgery of either knee within 6 months after the injection.
  16. Participant previously underwent arthroplasty (ie, full or partial knee replacement) of the target knee.
  17. Presence of joint instability or complaints of locking, intermittent limitation in range of motion, or loose body sensation, suggestive of internal derangement of the knee (either extremity).
  18. Diagnosis of lower extremity gout or pseudo-gout in the past 6 months prior to Screening.
  19. History of, or current manifestation of, osteonecrosis of either knee.
  20. Significant acute (within the past 3 months) injury to the target knee.
  21. History of receiving a solid organ or hematologic transplant.
  22. History of , radiotherapy, or chemotherapy for malignancy within the past 5 years, except for basal or squamous cell carcinoma of the skin.
  23. History of prior radiation therapy of the target knee.
  24. History of disease affecting the musculoskeletal system.
  25. Known (documented) history of acquired immune deficiency syndrome or (HIV).
  26. Any condition causing pain in or around the target knee (eg, radiating pain or pain in another region of the ipsilateral lower extremity) that may interfere with assessment(s) of the target knee.
  27. Other chronic pain anywhere in the body that requires the chronic use of analgesic medications, such as knee OA of the contralateral (non-target) knee, fibromyalgia, tendonitis, plantar fasciitis, neuropathic pain, lower back pain, etc.
  28. Known presence of any concurrent medical condition (eg, hematologic renal, hepatic, cardiac, or coagulation abnormalities) or other factors that in the Investigator's judgment would interfere with the required study assessments and study participation.
  29. Participant is involved in litigation (eg, worker's compensation) for a medical condition or injury at any anatomical site.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    PTP-001 200 mg

    A single intra-articular injection in the target knee of PTP-001 200 mg

    Biological: PTP-01

  • Placebo comparator
    Placebo / saline vehicle

    A single intra-articular injection in the target knee of 4 mL of placebo control (0.9% sodium chloride injection, USP)

    Other: Placebo control / saline vehicle

Interventions

  • BiologicalPTP-01

    Allogeneic human placental tissue particulate (PTP-001) is administered as a single intra-articular injection to the target knee after resuspension with saline.

    Also known as: MOTYS™, allogeneic human placental tissue particulate

  • OtherPlacebo control / saline vehicle

    The placebo control, physiological saline (0.9% sodium chloride injection, USP), is administered as an intra-articular injection to the target knee.

    Also known as: Normal saline, Physiological saline

06

What researchers measure

Primary outcomes

  1. Proportion of participants meeting strict responder criteria for improvement in knee function.

    To qualify as a "strict responder for improvement in knee function", an improvement of ≥ 50% in WOMAC Function subscale score is required, with an absolute change ≥ 20 points in the score.

    Time frame: 6 months

  2. Proportion of participants meeting strict responder criteria for improvement in knee pain.

    To qualify as a "strict responder for improvement in knee pain", an improvement of ≥ 50% in WOMAC Pain subscale score is required, with an absolute change ≥ 20 points in the score.

    Time frame: 6 months

Secondary outcomes

  1. Proportion of participants meeting strict responder criteria for improvement in knee function.

    Time frame: 9 months and 12 months

  2. Proportion of participants meeting strict responder criteria for improvement in knee pain.

    Time frame: 9 months and 12 months

  3. Change from pretreatment Baseline in participant self-reported assessment of OA by PGA-OA score.

    Time frame: 6 months, 9 months, and 12 months

  4. Change from pretreatment Baseline in participant self-reported function of the treated knee as assessed by WOMAC Function subscale score.

    Time frame: 6 months, 9 months, and 12 months

  5. Change from pretreatment Baseline in participant self-reported pain at the treated knee as assessed by WOMAC Pain subscale score.

    Time frame: 6 months, 9 months, and 12 months

07

Study locations

11 of 18 sites recruiting
08

References and documents

Publications

  • Flannery CR, Buddin KE, Begum L, Nasert MA, Catalfamo B, Semler EJ, Fortier LA. Composition and Bioactivity of a Placental Tissue Particulate (PTP-001) Indicate Greater Potential than Platelet-Rich Plasma for the Treatment of Osteoarthritis. Cartilage. 2023 Dec;14(4):467-472. doi: 10.1177/19476035231159748. Epub 2023 Mar 13. PubMed 36912174 ↗
  • Flannery CR, Seaman SA, Buddin KE, Nasert MA, Semler EJ, Kelley KL, Long M, Favret J, Pavesio A, Loeser RF. A novel placental tissue biologic, PTP-001, inhibits inflammatory and catabolic responses in vitro and prevents pain and cartilage degeneration in a rat model of osteoarthritis. Osteoarthritis Cartilage. 2021 Aug;29(8):1203-1212. doi: 10.1016/j.joca.2021.03.022. Epub 2021 May 20. PubMed 34023528 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jun 2027, 20 months after the start.

Of 65 industry-sponsored phase 3 interventional studies under Osteoarthritis, Knee, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 27. This study's planned 20 months is close to that.

Counting every sponsor, half of 101 studies reached it within 22 months; a quarter within 15 and three quarters within 35.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Apr 2027 → Jun 2027 and completion Oct 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2025
First posted
Oct 22, 2025
StartActual
Oct 14, 2025
Primary completionEst.
Jun 30, 2027was Apr 2027
CompletionEst.
Dec 30, 2027was Oct 2027
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed. 6 sites changed recruiting status (4 now active, not recruiting, 1 now withdrawn, …)
Show 6 sites
  • Lehigh Center for Clinical Research · Allentown, United StatesRecruiting→Withdrawn
  • Emeritus Research Sydney · Botany, AustraliaRecruiting→Terminated
  • Royal North Shore Hospital · St Leonards, AustraliaRecruiting→Active, not recruiting
  • University of the Sunshine Coast Clinical Trials, Birtinya · Birtinya, AustraliaRecruiting→Active, not recruiting
  • University of the Sunshine Coast Clinical Trials, Morayfield · Morayfield, AustraliaRecruiting→Active, not recruiting
  • Momentum Clinical Research Taringa · Taringa, AustraliaRecruiting→Active, not recruiting
Show 2 added (1 United States, 1 Australia)
  • Tucson Orthopaedic Institute · Tucson, United States
  • University of the Sunshine Coast Clinical Trials, Maroochydore · Maroochydore, Australia
Show 1 removed
  • University of the Sunshine Coast Clinical Trials, Noosa · Noosaville, Australia
Oct 16, 2026
Primary completion
Apr 2027→Jun 30, 2027
Oct 16, 2026
Study completion
Oct 2027→Dec 30, 2027
Oct 16, 2026
Enrollment
260→300
Oct 16, 2026
Eligibility
3 exclusion criteria edited
What changed in the criteria
Exclusion criteria
  • EditedContralateral (non-target) knee pain is ≥ >10 out of 50 on the WOMAC® NRS 3.1 pain questionnaire (sum of 5 questions) at Screening or at Baseline.
  • EditedAt Baseline, difference between the first Baseline and second Baseline WOMAC pain scores is ≥> 3 for the target knee.
  • ChangedBefore Severe (excessive) malalignment of the tibial-femoral axis assessed radiographically (by previous X-ray, rather than that performed for Kellgren-Lawrence assessment).Now Clinical and/or radiographic evidence (other than that performed for Kellgren-Lawrence eligibility assessment) of severe (excessive) malalignment of the tibial-femoral axis, as assessed by the Investigator.
Oct 16, 2026
Site contacts
Changed at 6 sites. See the sites
Show 6 sites
  • Lehigh Center for Clinical Research · Allentown, United StatesContact removed m•••@lehighcenter.com · •••0342Contact removed (no phone or email listed)
  • Emeritus Research Sydney · Botany, AustraliaContact removed r•••@emeritusresearch.com · •••8186Contact removed (no phone or email listed)
  • Royal North Shore Hospital · St Leonards, AustraliaContact removed s•••@sydney.edu.au · •••1887Contact removed (no phone or email listed)
  • University of the Sunshine Coast Clinical Trials, Birtinya · Birtinya, AustraliaContact removed p•••@usc.edu.au · •••3872Contact removed (no phone or email listed)
  • University of the Sunshine Coast Clinical Trials, Morayfield · Morayfield, AustraliaContact removed i•••@usc.edu.au · •••3965Contact removed (no phone or email listed)
  • Momentum Clinical Research Taringa · Taringa, AustraliaContact removed t•••@momentumclinicalresearch.com.au · •••5255Contact removed (no phone or email listed)
Oct 16, 2026
Title
A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P)
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    2 sites added, 1 site removed. 6 sites changed recruiting status (4 now active, not recruiting, 1 now withdrawn, …)
    Show 6 sites
    • Lehigh Center for Clinical Research · Allentown, United StatesRecruiting→Withdrawn
    • Emeritus Research Sydney · Botany, AustraliaRecruiting→Terminated
    • Royal North Shore Hospital · St Leonards, AustraliaRecruiting→Active, not recruiting
    • University of the Sunshine Coast Clinical Trials, Birtinya · Birtinya, AustraliaRecruiting→Active, not recruiting
    • University of the Sunshine Coast Clinical Trials, Morayfield · Morayfield, AustraliaRecruiting→Active, not recruiting
    • Momentum Clinical Research Taringa · Taringa, AustraliaRecruiting→Active, not recruiting
    Show 2 added (1 United States, 1 Australia)
    • Tucson Orthopaedic Institute · Tucson, United States
    • University of the Sunshine Coast Clinical Trials, Maroochydore · Maroochydore, Australia
    Show 1 removed
    • University of the Sunshine Coast Clinical Trials, Noosa · Noosaville, Australia
    Primary completion Apr 2027→Jun 30, 2027
    Study completion Oct 2027→Dec 30, 2027
    Enrollment 260→300
    Eligibility 3 exclusion criteria edited
    What changed in the criteria
    Exclusion criteria
    • EditedContralateral (non-target) knee pain is ≥ >10 out of 50 on the WOMAC® NRS 3.1 pain questionnaire (sum of 5 questions) at Screening or at Baseline.
    • EditedAt Baseline, difference between the first Baseline and second Baseline WOMAC pain scores is ≥> 3 for the target knee.
    • ChangedBefore Severe (excessive) malalignment of the tibial-femoral axis assessed radiographically (by previous X-ray, rather than that performed for Kellgren-Lawrence assessment).Now Clinical and/or radiographic evidence (other than that performed for Kellgren-Lawrence eligibility assessment) of severe (excessive) malalignment of the tibial-femoral axis, as assessed by the Investigator.
    Site contacts Changed at 6 sites. See the sites
    Show 6 sites
    • Lehigh Center for Clinical Research · Allentown, United StatesContact removed m•••@lehighcenter.com · •••0342Contact removed (no phone or email listed)
    • Emeritus Research Sydney · Botany, AustraliaContact removed r•••@emeritusresearch.com · •••8186Contact removed (no phone or email listed)
    • Royal North Shore Hospital · St Leonards, AustraliaContact removed s•••@sydney.edu.au · •••1887Contact removed (no phone or email listed)
    • University of the Sunshine Coast Clinical Trials, Birtinya · Birtinya, AustraliaContact removed p•••@usc.edu.au · •••3872Contact removed (no phone or email listed)
    • University of the Sunshine Coast Clinical Trials, Morayfield · Morayfield, AustraliaContact removed i•••@usc.edu.au · •••3965Contact removed (no phone or email listed)
    • Momentum Clinical Research Taringa · Taringa, AustraliaContact removed t•••@momentumclinicalresearch.com.au · •••5255Contact removed (no phone or email listed)
    Title A Study to Evaluate the Efficacy and Safey of PTP-001 (MOTYS™) in Knee Osteoarthritis Patients (MOTION-P)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07219771
Lead sponsor
Doron Therapeutics Inc.
Collaborators
Novotech (Australia) Pty Limited
Responsible party
Sponsor
First posted
Oct 22, 2025
Start date
Oct 14, 2025
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 30, 2027 (estimated)
Last update
Oct 16, 2026

Study contacts

Mary Kathryn Kottke
Contact
mk.kottke@dorontherapeutics.com
919-355-4630
Professor David Hunter
principal investigator · Chair of Rheumatology at University of Sydney and Royal North Shore Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion